IPCALAB.NS Ipca Laboratories Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 276397 | 146091 | 52.86% |
| 2026-08-27 | 122184 | 66244 | 54.22% |
| 2026-08-26 | 455426 | 199017 | 43.70% |
| 2026-08-25 | 427720 | 197280 | 46.12% |
| 2026-08-24 | 277434 | 156625 | 56.45% |
| 2026-08-21 | 194059 | 96029 | 49.48% |
| 2026-08-20 | 236586 | 125393 | 53.00% |
| 2026-08-19 | 753334 | 327341 | 43.45% |
| 2026-08-18 | 804532 | 227329 | 28.26% |
| 2026-08-17 | 6964903 | 1349517 | 19.38% |
| 2026-08-14 | 390591 | 183144 | 46.89% |
| 2026-08-13 | 1835473 | 334220 | 18.21% |
| 2026-08-12 | 149151 | 73817 | 49.49% |
| 2026-08-11 | 233132 | 99439 | 42.65% |
| 2026-08-10 | 239283 | 130689 | 54.62% |
| 2026-08-07 | 79829 | 38218 | 47.87% |
| 2026-08-06 | 151963 | 78112 | 51.40% |
| 2026-08-05 | 290079 | 150742 | 51.97% |
| 2026-08-04 | 222711 | 137201 | 61.60% |
| 2026-08-03 | 159711 | 91744 | 57.44% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers IPCALAB.NS to fetch more history.
Insider trading activity
| Disclosed | Person | Category | Type | Mode | Quantity | Value (₹) | Resulting stake | |
|---|---|---|---|---|---|---|---|---|
| 18 Feb 2026 | MANISH KUMAR JAIN | - | Sell | Market Sale | 3000 | 4446655 | 0.01% | XBRL |
| 25 Aug 2025 | Pawan Kothari | Employees/Designated Employees | Sell | Market Sale | 2220 | 3136908 | 0.00% | XBRL |
| 21 Aug 2025 | Mexin Medicaments Pvt. Ltd. | Promoter Group | Sell | Others | 14058 | 0 | 0.00% | XBRL |
| 21 Aug 2025 | Kaygee Investments Private Limited | Promoter Group | Buy | Others | 10187058 | 0 | 25.49% | XBRL |
| 21 Aug 2025 | Paschim Chemicals Private Limited | Promoter Group | Sell | Others | 10173000 | 0 | 0.00% | XBRL |
| 19 Dec 2024 | Mrs. Usha M. Chandurkar | - | Sell | - | 4000000 | 5996983044 | 1.70% | XBRL |
| 12 Mar 2024 | Paschim Chemicals Private Limited | Promoter Group | Buy | Market Purchase | 35000 | 42033789 | 4.01% | XBRL |
| 20 Nov 2023 | Mr. Ajit Kumar JainAADPJ2602A | - | Sell | Market Sale | 20000 | 21636933 | 0.02% | XBRL |
| 19 Sep 2022 | E J BABU | Other | Sell | Market Sale | 2000 | 1748770 | 0.01% | XBRL |
| 04 Aug 2022 | Mrs. Usha Chandurkar | Promoter Group | Buy | Others | 4000000 | 0 | 3.27% | XBRL |
| 01 Aug 2022 | Mrs. Usha Chandurkar | Promoter Group | Buy | Others | 302000 | 0 | 1.70% | XBRL |
| 21 Mar 2022 | Ajit Kumar Jain | Director | Sell | Market Sale | 20000 | 20536337 | 0.02% | XBRL |
| 26 Aug 2021 | Kavita Sehwani | Employees/Designated Employees | Sell | Market Sale | 450 | 1098521 | 0.02% | XBRL |
| 23 Aug 2021 | Pabitra Kumar Bhattacharyya | Employees/Designated Employees | Sell | Market Sale | 4000 | 10040000 | 0.00% | XBRL |
| 19 Aug 2021 | Ajit Kumar Jain | Director | Sell | Market Sale | 10000 | 24218979 | 0.03% | XBRL |
| 13 Aug 2021 | Dr. Anil Kumar Pareek | Employees/Designated Employees | Sell | Market Sale | 1597 | 3806134 | 0.01% | XBRL |
| 30 Mar 2021 | Dr. Goutam Muhuri | Employees/Designated Employees | Buy | Market Purchase | 1000 | 1887345 | 0.00% | XBRL |
| 25 Feb 2021 | Harish Kamath | Employees/Designated Employees | Sell | Market Sale | 7000 | 12735728 | 0.00% | XBRL |
| 14 Dec 2020 | Dr. Ashok Kumar | Employees/Designated Employees | Sell | Market Sale | 1000 | 2250000 | 0.03% | XBRL |
| 25 Nov 2020 | Dr. Ashok Kumar | Employees/Designated Employees | Sell | Market Sale | 500 | 1100000 | 0.03% | XBRL |
SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers IPCALAB.NS to fetch more.
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
ROCE Trajectory
Earnings Quality
⚠ Persistent profit/cash gap
Net Profit CAGR 34.27% vs CFO CAGR 12.32% over 3.0y (2023-03-31 → 2026-03-31); most recent year: Net Profit +54.69% vs CFO -13.57%
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q4 FY2023-24 | Q1 FY2024-25 | Q2 FY2024-25 | Q3 FY2024-25 | Q4 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,033.01 Cr. | ₹2,092.63 Cr. | ₹2,354.90 Cr. | ₹2,245.37 Cr. | ₹2,246.69 Cr. | ₹2,308.85 Cr. | ₹2,556.50 Cr. | ₹2,392.50 Cr. | ₹2,388.48 Cr. | ₹2,788.10 Cr. | RevenueFromOperations |
| Net Profit | ₹59.59 Cr. incl. minority ₹1.33 Cr. | ₹192.24 Cr. incl. minority ₹199.14 Cr. | ₹229.48 Cr. incl. minority ₹245.75 Cr. | ₹248.14 Cr. incl. minority ₹276.36 Cr. | ₹67.82 Cr. incl. minority ₹63.99 Cr. | ₹233.21 Cr. incl. minority ₹232.89 Cr. | ₹282.57 Cr. incl. minority ₹280.53 Cr. | ₹326.27 Cr. incl. minority ₹363.67 Cr. | ₹299.07 Cr. incl. minority ₹306.69 Cr. | ₹401.89 Cr. incl. minority ₹424.27 Cr. | ProfitOrLossAttributableToOwnersOfParent |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers IPCALAB.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitOrLossAttributableToOwnersOfParent | 11411200000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 253700000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 63736100000.0 |
| CurrentLiabilities | 23069300000.0 |
| EquityAttributableToOwnersOfParent | 80638100000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | 7039400000.0 |